Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Res...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2013 |
| Автори: | , , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2013
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/145263 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Receptor status of tumor as prognostic factor in patients with bilateral breast cancer / D.Y. Tsyhyka, Y.S. Hotko, O.T. Devinyak // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 291-294. — Бібліогр.: 11 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| Резюме: | Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Results: Patients with metachronous BBC with positive status of hormone receptors (HR) of tumors have significantly better indices of overall and progression-free survival (three-years — 95%, five-years — 72%), than patients with HR-negative status (among them nobody has survived over 5 years). In patients with synchronous BBC, the receptor status of tumors has similar influence on the prognosis of survival. Nevertheless, indices of overall survival (65%) and progression-free survival (66%) in HR-positive patients were lower than that at metachronous BBC (overall survival and progression-free survival — 72%). Conclusions: Synchronous breast cancer has more aggressive clinical course than metachronous one. It was determined significant influence of receptor status of tumors on the overall survival and progression-free survival in patients with BBC.
|
|---|---|
| ISSN: | 1812-9269 |